Clinical Trials Logo

Cholestasis, Intrahepatic clinical trials

View clinical trials related to Cholestasis, Intrahepatic.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04718961 Terminated - Clinical trials for Intrahepatic Cholestasis of Pregnancy

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

OHANA
Start date: January 4, 2021
Phase: Phase 2
Study type: Interventional

This is a two-part randomized study of volixibat in patients with Intrahepatic Cholestasis of Pregnancy (ICP) and elevated serum bile acid concentrations (sBA). Part 1 is an open-label study to evaluate safety and tolerability of two doses of volixibat. Part 2 is a double-blind, placebo controlled, study designed to evaluate the safety and efficacy of a selected volixibat dose.

NCT ID: NCT01383746 Terminated - Clinical trials for Cholestasis, Progressive Familial Intrahepatic 3

Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION

CHOLANGIOSIR
Start date: October 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Cholangiocarcinoma (CCK) is a rare tumor (2000 new cases/year in France) with very poor prognosis (overall survival < 3% at 5 years). Less than 20% of patients may benefit from curative surgical resection and most patients have medical treatment by palliative treatment by palliative chemotherapy. It is not standard first-line chemotherapy validated for unresectable CCK, but the best objective response rate (OR) and overall survival (OS) are observed with gemcitabine and platinum associations (OR 24 to 36% and OS between 9.5 to 15.4 months). In case of tumor progression ater this first line therapy, no treatment is currently being validated. RADIOEMBOLIZATION (RE) is a new, transarterial approach to radiation therapy using 90 Yttrium microspheres. In the patients with unresectable CCK , the first pilot studies showed interesting results with rates of OR 45 to 90% and a median OS of 14.9 mots and an acceptable safety. Study Hypothesis : RE could help achieve tumor stabilization in patients with intra-hepatic CCK in tumor progression after first-line therapy.